Results for tag: "Mantle Cell Lymphoma"

Mantle Cell Lymphoma (MCL) is a type of non-Hodgkin lymphoma that arises from the outer edge of a lymph node follicle (the mantle zone) and is characterized by the malignant growth of B lymphocytes. Within the broader context of lymphoma drugs, the market for MCL treatments is focused on addressing the aggressive nature of the condition, which often makes standard chemotherapy less effective. The therapeutic landscape for MCL includes a variety of approaches such as targeted therapies, immunotherapy, combination therapies, and stem cell transplantation. In recent years, the MCL market has seen the introduction of novel agents that target specific pathways involved in the pathogenesis of the disease. These agents include kinase inhibitors, proteasome inhibitors, and monoclonal antibodies, some of which have been granted breakthrough therapy designations for providing improved outcomes over traditional treatment options. Additionally, the treatment paradigm for MCL is shifting toward personalized medicine, considering the genetic profile of the patient's cancer to inform therapy choices. Several pharmaceutical and biotechnology companies are active in the MCL market. Among these are Janssen Biotech, which markets ibrutinib, a Bruton's tyrosine kinase (BTK) inhibitor; AstraZeneca, with acalabrutinib, another BTK inhibitor; Bayer, the company behind the proteasome inhibitor copanlisib; AbbVie, co-developing venetoclax, a BCL-2 inhibitor Show Less Read more